Exploring the antimicrobial potential of 4,5,7-trihydroxyflavanone (THF) against vancomycin-resistant Enterococcus gallinarum infections: in vitro and in silico investigations

Enterococcus gallinarum and other Enterococcus species commonly inhabit the human gastrointestinal tract. While the pathogenicity of Enterococcus gallinarum remains incompletely understood, its infections are alarmingly severein humans, as evidenced by numerous cases. Formerly, Vancomycin was the preferred drug, but recent findings indicate that clinical isolates of Enterococcus gallinarum are resistant, leading to the emergence of vancomycin-resistant enterococci (VRE) strains. The escalation of drug resistance is often linked to overexpressed virulence factors, some of which are implicated in biofilm formation in Enterococcus infections. Henceforth, this research investigates the potential of phytocompounds to combat E. gallinarum infection, employing both in vitro and in silico methodologies. In vitro techniques were employed to assess the efficacy of various phytocompounds, ultimately identifying 4,5,7-trihydroxyflavanone (THF) as particularly effective in inhibiting microbial growth. THF displayed over 80% antibacterial activity at 200 µg/ml against E. gallinarum. Subsequent qualitative and quantitative hemolysin assays implicated hemolysin as a target of THF. Molecular docking analysis of THF and Hemolysin A revealed a strong binding affinity. Notably, residues Asn18, Asp85, and His199 formed hydrogen bonds, while His22 and His86 were involved in robust π-π stacking and π-cation interactions with THF. Overall, this study highlights THF's potential in combating E. gallinarum infections.

Communicated by Ramaswamy H. Sarma